Loading
Total declarations
Companies
▲ Purchases (15 ops.)
▼ Sales (5 ops.)
Latest filing published 12 Jul 2018 for Loxo Oncology, Inc., €214.2M.
Filing timeline
BuySaleAisling Capital III LP
Insider track record
Disclosed buys
15
Disclosed sells
5
Signal history
Closed purchases
Market purchases
15
Positive at T+90
0%
Median T+90
-14.0%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -48.9%Entry US$957.00 · Close at T+365 US$489.00
- -31.0%Entry US$1,959.00 · Close at T+365 US$1,351.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Aisling Capital III LP: trading record in brief
Aisling Capital III LP discloses dealings in 7 companies, chiefly Loxo Oncology, Inc., Aravive, Inc. and Durata Therapeutics, Inc. Between 24 July 2012 and 10 July 2018, the trades on record add up to 33 filings.
Both buying and selling appear: 15 purchases worth €51.3M, against 5 sales worth €264.4M. The net balance comes to €213.0M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2018 alone, the filings show no purchases and 1 sale.
A typical purchase (the median) is worth €3.7M.
The latest filing, published on 12 July 2018, reports an open-market sale of €214.2M in Loxo Oncology, Inc. The latest purchase dates back some time: it was published 3,571 days ago, on 12 January 2017. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Aisling Capital III LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations32 total
1,400,000 shares@ US$179.4381.4% of flowCommon StockSEC:0000899243-18-019810:0
250,000 shares@ US$80.506.3% of flowCommon StockSEC:0000950142-17-002235:0
500,000 shares@ US$75.0011.7% of flowCommon StockSEC:0000950142-17-002107:0
160,000 shares@ US$31.001.7% of flowCommon StockSEC:0000950142-17-000108:0
Canonical exit: 10 Apr 2017 (T+90)
508,565 sharesCommon StockSEC:0000950142-16-004060:0
400,000 shares@ US$12.50Common StockSEC:0000950142-16-004060:1
Canonical exit: 4 Oct 2016 (T+90)
400,000 shares0Common StockSEC:0000950142-16-003866:0
232,558 shares@ US$21.501.6% of flowCommon StockSEC:0000950142-16-003763:0
Canonical exit: 15 Aug 2016 (T+90)
200 shares@ US$27.50Common StockSEC:0000950142-15-002621:0
Canonical exit: 10 Mar 2016 (T+90)
307,692 shares@ US$9.75Common StockSEC:0000950142-15-002576:0
Canonical exit: 8 Mar 2016 (T+90)
265,000 shares@ US$26.50Common StockSEC:0000950142-15-002461:0
Canonical exit: 15 Feb 2016 (T+90)
76,714 shares@ US$27.6523Common StockSEC:0000950142-15-002434:0
Canonical exit: 10 Feb 2016 (T+90)
1,955 shares@ US$27.4702Common StockSEC:0000950142-15-002434:1
Canonical exit: 11 Feb 2016 (T+90)
145,000 shares@ US$17.25Common StockSEC:0000950142-15-000194:0
Canonical exit: 27 Apr 2015 (T+90)
2,068,755 shares0Common StockSEC:0001104659-14-061090:0
454,545 shares@ US$11.00Common StockSEC:0001104659-14-061090:1
Canonical exit: 10 Nov 2014 (T+90)
2,850,709 shares0Common StockSEC:0001140361-14-031039:0
413,077 shares@ US$13.00Common StockSEC:0001140361-14-031039:1
Canonical exit: 4 Nov 2014 (T+90)
745,730 shares0Common StockSEC:0000950142-14-001096:0
3,528 shares0Common StockSEC:0000950142-14-001096:1
1,037,767 shares@ US$4.00Common StockSEC:0000950142-14-000941:0
Canonical exit: 20 Jul 2014 (T+90)
35,104 sharesCommon StockSEC:0001209191-14-023549:0
1,236,715 sharesCommon StockSEC:0001209191-14-023549:1
128,695 sharesCommon StockSEC:0001209191-14-023549:2
56,939 sharesCommon StockSEC:0001209191-14-023549:3
25 of 32 declarations
